HC Wainwright Has Negative Forecast for ONCY FY2026 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities researchers at HC Wainwright decreased their FY2026 earnings estimates for Oncolytics Biotech in a research report issued to clients and investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.30) for the year, down from their previous estimate of ($0.28). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.19) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.00 EPS.

Several other research firms have also recently commented on ONCY. Weiss Ratings upgraded shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Oncolytics Biotech Stock Performance

Shares of ONCY opened at $0.80 on Friday. The firm has a fifty day moving average of $0.86 and a 200-day moving average of $0.92. The company has a market cap of $102.23 million, a price-to-earnings ratio of -2.36 and a beta of 1.13. Oncolytics Biotech has a 1 year low of $0.73 and a 1 year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03).

Institutional Investors Weigh In On Oncolytics Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of ONCY. Renaissance Technologies LLC acquired a new stake in Oncolytics Biotech in the first quarter worth about $608,000. Citadel Advisors LLC acquired a new position in Oncolytics Biotech during the 3rd quarter valued at about $535,000. Connective Capital Management LLC bought a new stake in shares of Oncolytics Biotech during the 4th quarter worth about $131,000. Susquehanna International Group LLP raised its position in shares of Oncolytics Biotech by 224.6% during the 2nd quarter. Susquehanna International Group LLP now owns 134,129 shares of the company’s stock worth $127,000 after buying an additional 92,806 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Oncolytics Biotech in the 4th quarter worth approximately $69,000. 6.82% of the stock is currently owned by institutional investors.

Key Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Oncolytics Biotech gained FDA alignment on its REO 033 trial, potentially reducing regulatory uncertainty and supporting the development path for its oncology candidate. Oncolytics Biotech gains FDA alignment on REO 033 trial
• Positive Sentiment: HC Wainwright maintained its Buy rating and a $5.00 price target. Based on the referenced $0.80 share price, the target indicates substantial potential upside, although it remains dependent on successful clinical and commercial execution. HC Wainwright Lowers Oncolytics Biotech Price Target to $5.00
• Neutral Sentiment: ONCY opened at $0.80, below its 50-day and 200-day moving averages of $0.86 and $0.92, respectively, and near its 52-week low of $0.73. This reflects weak recent trading momentum despite the analyst’s bullish rating.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods: FY2026 to a loss of $0.30 from $0.28, FY2027 to a loss of $0.21 from $0.15, FY2028 to a loss of $0.19 from $0.14, FY2029 to a loss of $0.19 from $0.12, and FY2030 to breakeven from projected earnings of $0.14. Quarterly estimates for Q4 2026, Q2 2027, Q3 2027 and Q4 2027 were also lowered.
• Negative Sentiment: The estimate revisions suggest analysts expect slower profitability improvement and continued cash-burn risk. Oncolytics previously reported a quarterly loss of $0.08 per share, worse than the $0.05 consensus estimate, while the broader current-year consensus remains a loss of $0.25 per share.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.